Cost implications of lipid-lowering treatments.
Coronary heart disease (CHD) is the major cause of morbidity and mortality in the Western world, and contributes substantially to global healthcare costs.  As pressure rises to certain health costs, it is essential to consider the cost-effectiveness of different management strategies. In terms of CHD, treatment costs for different procedures for existing disease can be considered, and can also be compared with the costs of prevention programmes.
Reckless
J P
JP
School of Postgraduate Medicine, University of Bath, Royal United Hospital, England.
D000924:Anticholesteremic Agents / Q000191:economics* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D017281:Cost of Illness; D003362:Cost-Benefit Analysis / Q000639:trends; D005544:Forecasting; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000517:prevention & control; D015994:Incidence; D011788:Quality of Life; D012307:Risk Factors; D016896:Treatment Outcome